Tamoxifen for breast cancer chemoprevention: low uptake by high-risk women after evaluation of a breast lump
about
Factors affecting uptake and adherence to breast cancer chemoprevention: a systematic review and meta-analysisBarriers to preventive therapy for breast and other major cancers and strategies to improve uptakeThe National Cancer Institute of Canada Clinical Trials Group MAP.3 trial: an international breast cancer prevention trialAtypical hyperplasia of the breast--risk assessment and management options.Patient decisions about breast cancer chemoprevention: a systematic review and meta-analysis.Impact of self-reported data on the acquisition of multi-generational family history and lifestyle factors among women seen in a high-risk breast screening program: a focus on modifiable risk factors and genetic referral.Willingness to use tamoxifen to prevent breast cancer among diverse women.How do we increase uptake of tamoxifen and other anti-estrogens for breast cancer prevention?Prevalence of tamoxifen use for breast cancer chemoprevention among U.S. women.Breast Cancer Chemoprevention among High-risk Women and those with Ductal Carcinoma In Situ.Making hard choices easier: a prospective, multicentre study to assess the efficacy of a fertility-related decision aid in young women with early-stage breast cancer.Awareness of preventive medication among women at high risk for breast cancer and their willingness to consider transdermal or oral tamoxifen: a focus group study.Acceptance and adherence to chemoprevention among women at increased risk of breast cancerChoices for young women at intermediate risk of breast cancerImpact of preventive therapy on the risk of breast cancer among women with benign breast disease.Uptake of exemestane chemoprevention in postmenopausal women at increased risk for breast cancer.Chemoprevention of Breast Cancer: The Paradox of Evidence versus Advocacy Inaction.Tamoxifen vs Raloxifene vs Exemestane for ChemopreventionUse of tamoxifen and raloxifene for breast cancer chemoprevention in 2010Validity assessment of the Breast Cancer Risk Reduction Health Belief scale.Uptake of tamoxifen in consecutive premenopausal women under surveillance in a high-risk breast cancer clinic.Chemoprevention Uptake among Women with Atypical Hyperplasia and Lobular and Ductal Carcinoma In Situ.Motivators and barriers of tamoxifen use as risk-reducing medication amongst women at increased breast cancer risk: a systematic literature review.In This Issue: Bursting the Bubble on Chronic Disease Management, the Meaning of Healing, PBRN Methods Supplement, and the Annals’ 2-Year Anniversary.Deciding on breast cancer risk reduction: The role of counseling in individual decision-making - A qualitative study.CYP2D6*3 (A2549del), *4 (G1846A), *10 (C100T) and *17 (C1023T) genetic polymorphisms in Iranian breast cancer patients treated with adjuvant tamoxifen
P2860
Q26773464-A3D6B473-DD9D-44E5-9592-E5B31C2EA365Q26774593-87B4CA48-5B34-45F2-9D76-F7AB2F4AA2ADQ28217652-16215BAC-C9A8-4B02-A01C-A6DADF0C82B1Q30301033-4B0E833E-155B-4B9E-A1A6-361D610CEED3Q30431831-D706D98D-19E8-4693-A701-455DB2A0A32FQ31157610-C7AADC8D-33D8-48F5-B04C-04C2B5AE93F5Q33688754-18152E98-6338-42BA-8E6B-DAC384173094Q33767120-6DBC8FA8-9D92-4466-AA4F-62A09FE3EC4BQ34573294-7C66440B-FA8C-4045-B077-A9FAED3802A4Q35812120-AC9811C1-0138-4D07-83BD-6591457C4222Q35832375-54C1D260-B8BB-4809-A3C0-E87B9763ED34Q35836307-A2E60616-A3B5-42A5-A186-721B89D795D8Q35854935-A9E19EEA-BD76-4F0F-B583-6D9275BB2B9FQ36000212-342D8C9D-D435-4704-9282-213275885A56Q36258270-D70408EA-545A-4F24-A30F-1C3F89F83DA7Q36947842-35A5D11B-B3E0-41F4-96F1-0684528DF608Q37017096-412A9B13-B099-46C2-B90B-166B250243D5Q37097084-BBEC20D3-E7DA-4D66-99DF-9D0885117C96Q37165630-3C99554B-3F09-4CA7-8FC7-EFB08E755C42Q37400617-AF416B2A-3463-4F0B-AF4E-AF4AF79BF7F9Q37681706-F01C3171-DCBF-4B4D-B5BB-277B46FDEB66Q38727084-E84BF757-7BC7-4F75-9083-89F66768F498Q41696217-D33D1B2B-98E4-40FD-9D71-B7989D661E60Q45815909-D26FBC65-FB73-4864-8B46-6B039DD58302Q51837751-D03316F9-A8DF-47A5-B980-8D624EECDA5AQ57786811-09B4D2EB-B6E7-425A-828B-6B025FD7D9C3
P2860
Tamoxifen for breast cancer chemoprevention: low uptake by high-risk women after evaluation of a breast lump
description
2005 nî lūn-bûn
@nan
2005 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Tamoxifen for breast cancer ch ...... er evaluation of a breast lump
@ast
Tamoxifen for breast cancer ch ...... er evaluation of a breast lump
@en
Tamoxifen for breast cancer ch ...... er evaluation of a breast lump
@nl
type
label
Tamoxifen for breast cancer ch ...... er evaluation of a breast lump
@ast
Tamoxifen for breast cancer ch ...... er evaluation of a breast lump
@en
Tamoxifen for breast cancer ch ...... er evaluation of a breast lump
@nl
prefLabel
Tamoxifen for breast cancer ch ...... er evaluation of a breast lump
@ast
Tamoxifen for breast cancer ch ...... er evaluation of a breast lump
@en
Tamoxifen for breast cancer ch ...... er evaluation of a breast lump
@nl
P2860
P356
P1476
Tamoxifen for breast cancer ch ...... er evaluation of a breast lump
@en
P2093
Kenneth Taguchi
Rebecca Taylor
P2860
P304
P356
10.1370/AFM.284
P407
P577
2005-05-01T00:00:00Z